Cargando…
Derivation and validation of a lipid-covered prognostic model for mature T-cell lymphomas
BACKGROUND: Mature T-cell lymphomas (MTCLs), a group of diseases with high aggressiveness and vulnerable prognosis, lack for the accurate prognostic stratification systems at present. Novel prognostic markers and models are urgently demanded. Aberrant lipid metabolism is closely related to the tumor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256497/ https://www.ncbi.nlm.nih.gov/pubmed/34225710 http://dx.doi.org/10.1186/s12935-021-02042-3 |
_version_ | 1783718114708422656 |
---|---|
author | Lu, Tiange Shi, Lei Shi, Guanggang Cai, Yiqing Hu, Shunfeng Liu, Jiarui Ren, Shuai Zhou, Xiangxiang Wang, Xin |
author_facet | Lu, Tiange Shi, Lei Shi, Guanggang Cai, Yiqing Hu, Shunfeng Liu, Jiarui Ren, Shuai Zhou, Xiangxiang Wang, Xin |
author_sort | Lu, Tiange |
collection | PubMed |
description | BACKGROUND: Mature T-cell lymphomas (MTCLs), a group of diseases with high aggressiveness and vulnerable prognosis, lack for the accurate prognostic stratification systems at present. Novel prognostic markers and models are urgently demanded. Aberrant lipid metabolism is closely related to the tumor progression but its prognostic significance in MTCLs remains unexplored. This study aims to investigate the relationship between dysregulated lipid metabolism and survival prognosis of MTCLs and establish a novel and well-performed prognostic scoring system for MTCL patients. METHODS: A total of 173 treatment-naive patients were enrolled in this study. Univariate and multivariate Cox regression analysis were performed to assess the prognostic significance of serum lipid profiles and screen out independent prognostic factors, which constituted a novel prognostic model for MTCLs. The performance of the novel model was assessed in the training and validation cohort, respectively, by examining its calibration, discrimination and clinical utility. RESULTS: Among the 173 included patients, 115 patients (01/2006–12/2016) constituted the training cohort and 58 patients (01/2017–06/2020) formed the validation cohort. Univariate analysis revealed declined total cholesterol (TC, P = 0.000), high-density lipoprotein cholesterol (HDL-C, P = 0.000) and increased triglycerides (TG, P = 0.000) correlated to inferior survival outcomes. Multivariate analysis revealed extranodal involved sites ≥ 2 (hazard ratio [HR]: 2.439; P = 0.036), β2-MG ≥ 3 mg/L (HR: 4.165; P = 0.003) and TC < 3.58 mmol/L (HR: 3.338; P = 0.000) were independent predictors. Subsequently, a novel prognostic model, EnBC score, was constructed with these three factors. Harrell’s C-index of the model in the training and validation cohort was 0.840 (95% CI 0.810–0.870) and 0.882 (95% CI 0.822–0.942), respectively, with well-fitted calibration curves. The model divided patients into four risk groups with distinct OS [median OS: not available (NA) vs. NA vs. 14.0 vs. 4.0 months, P < 0.0001] and PFS (median PFS: 84.0 vs. 19.0 vs. 8.0 vs. 1.5 months, P < 0.0001). Time-dependent receiver operating characteristic curve and decision curve analysis further revealed that EnBC score provided higher diagnostic capacity and clinical benefit, compared with International Prognostic Index (IPI). CONCLUSION: Firstly, abnormal serum lipid metabolism was demonstrated significantly related to the survival of MTCL patients. Furthermore, a lipid-covered prognostic scoring system was established and performed well in stratifying patients with MTCLs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02042-3. |
format | Online Article Text |
id | pubmed-8256497 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-82564972021-07-06 Derivation and validation of a lipid-covered prognostic model for mature T-cell lymphomas Lu, Tiange Shi, Lei Shi, Guanggang Cai, Yiqing Hu, Shunfeng Liu, Jiarui Ren, Shuai Zhou, Xiangxiang Wang, Xin Cancer Cell Int Primary Research BACKGROUND: Mature T-cell lymphomas (MTCLs), a group of diseases with high aggressiveness and vulnerable prognosis, lack for the accurate prognostic stratification systems at present. Novel prognostic markers and models are urgently demanded. Aberrant lipid metabolism is closely related to the tumor progression but its prognostic significance in MTCLs remains unexplored. This study aims to investigate the relationship between dysregulated lipid metabolism and survival prognosis of MTCLs and establish a novel and well-performed prognostic scoring system for MTCL patients. METHODS: A total of 173 treatment-naive patients were enrolled in this study. Univariate and multivariate Cox regression analysis were performed to assess the prognostic significance of serum lipid profiles and screen out independent prognostic factors, which constituted a novel prognostic model for MTCLs. The performance of the novel model was assessed in the training and validation cohort, respectively, by examining its calibration, discrimination and clinical utility. RESULTS: Among the 173 included patients, 115 patients (01/2006–12/2016) constituted the training cohort and 58 patients (01/2017–06/2020) formed the validation cohort. Univariate analysis revealed declined total cholesterol (TC, P = 0.000), high-density lipoprotein cholesterol (HDL-C, P = 0.000) and increased triglycerides (TG, P = 0.000) correlated to inferior survival outcomes. Multivariate analysis revealed extranodal involved sites ≥ 2 (hazard ratio [HR]: 2.439; P = 0.036), β2-MG ≥ 3 mg/L (HR: 4.165; P = 0.003) and TC < 3.58 mmol/L (HR: 3.338; P = 0.000) were independent predictors. Subsequently, a novel prognostic model, EnBC score, was constructed with these three factors. Harrell’s C-index of the model in the training and validation cohort was 0.840 (95% CI 0.810–0.870) and 0.882 (95% CI 0.822–0.942), respectively, with well-fitted calibration curves. The model divided patients into four risk groups with distinct OS [median OS: not available (NA) vs. NA vs. 14.0 vs. 4.0 months, P < 0.0001] and PFS (median PFS: 84.0 vs. 19.0 vs. 8.0 vs. 1.5 months, P < 0.0001). Time-dependent receiver operating characteristic curve and decision curve analysis further revealed that EnBC score provided higher diagnostic capacity and clinical benefit, compared with International Prognostic Index (IPI). CONCLUSION: Firstly, abnormal serum lipid metabolism was demonstrated significantly related to the survival of MTCL patients. Furthermore, a lipid-covered prognostic scoring system was established and performed well in stratifying patients with MTCLs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02042-3. BioMed Central 2021-07-05 /pmc/articles/PMC8256497/ /pubmed/34225710 http://dx.doi.org/10.1186/s12935-021-02042-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Primary Research Lu, Tiange Shi, Lei Shi, Guanggang Cai, Yiqing Hu, Shunfeng Liu, Jiarui Ren, Shuai Zhou, Xiangxiang Wang, Xin Derivation and validation of a lipid-covered prognostic model for mature T-cell lymphomas |
title | Derivation and validation of a lipid-covered prognostic model for mature T-cell lymphomas |
title_full | Derivation and validation of a lipid-covered prognostic model for mature T-cell lymphomas |
title_fullStr | Derivation and validation of a lipid-covered prognostic model for mature T-cell lymphomas |
title_full_unstemmed | Derivation and validation of a lipid-covered prognostic model for mature T-cell lymphomas |
title_short | Derivation and validation of a lipid-covered prognostic model for mature T-cell lymphomas |
title_sort | derivation and validation of a lipid-covered prognostic model for mature t-cell lymphomas |
topic | Primary Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256497/ https://www.ncbi.nlm.nih.gov/pubmed/34225710 http://dx.doi.org/10.1186/s12935-021-02042-3 |
work_keys_str_mv | AT lutiange derivationandvalidationofalipidcoveredprognosticmodelformaturetcelllymphomas AT shilei derivationandvalidationofalipidcoveredprognosticmodelformaturetcelllymphomas AT shiguanggang derivationandvalidationofalipidcoveredprognosticmodelformaturetcelllymphomas AT caiyiqing derivationandvalidationofalipidcoveredprognosticmodelformaturetcelllymphomas AT hushunfeng derivationandvalidationofalipidcoveredprognosticmodelformaturetcelllymphomas AT liujiarui derivationandvalidationofalipidcoveredprognosticmodelformaturetcelllymphomas AT renshuai derivationandvalidationofalipidcoveredprognosticmodelformaturetcelllymphomas AT zhouxiangxiang derivationandvalidationofalipidcoveredprognosticmodelformaturetcelllymphomas AT wangxin derivationandvalidationofalipidcoveredprognosticmodelformaturetcelllymphomas |